Amebiasis Global Market Report 2025

The amebiasis market size has grown strongly in recent years. It will grow from $0.82 billion in 2024 to $0.88 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth during the historic period can be attributed to the rising incidence of amoebic infections in tropical regions, inadequate sanitation and hygiene practices in developing countries, increased international travel to endemic areas, greater awareness of the disease, and limited access to clean drinking water in rural areas.

The amebiasis market size is expected to see strong growth in the next few years. It will grow to $1.14 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period is expected to be driven by the rising prevalence of immunocompromised populations, increasing government efforts to enhance sanitation and healthcare infrastructure, growing investments in research for new treatments, a stronger focus on health initiatives to combat parasitic diseases, and the rising demand for effective oral medications. Key trends during this period include the increasing adoption of combination therapies, the development of vaccines, advancements in drug delivery systems, progress in pharmaceutical research, and the creation of novel antiprotozoal drugs.

The rising incidence of parasitic infections is expected to drive the growth of the amebiasis market. Parasitic infections are caused by organisms such as protozoa, helminths, or ectoparasites that live on or inside a host, deriving nutrients at the host's expense. Various factors, including increased travel, climate change, poor sanitation, and growing drug resistance, contribute to the spread and persistence of these infections. Amebiasis, caused by the Entamoeba histolytica parasite, plays a significant role in parasitic infections by invading the intestines and leading to symptoms such as diarrhea, abdominal pain, and severe complications such as tissue damage and liver abscesses. For example, in January 2024, the Animal and Plant Health Agency, a UK-based government agency, reported 1,071 cases of Parasitic Gastroenteritis (PGE) in 2022, including 190 cases of haemonchosis and 95 cases of nematodirosis. The number of haemonchosis cases was notably higher than in the previous year. As a result, the increasing prevalence of parasitic infections is fueling the expansion of the amebiasis market.

The widespread issue of poor sanitation is also contributing to the growth of the amebiasis market. Poor sanitation, which includes inadequate access to clean water, improper sewage disposal, and unhygienic facilities, facilitates the spread of infectious diseases. The lack of proper waste management, insufficient infrastructure, rapid urbanization, and limited access to clean water, especially in developing regions, are key factors driving the prevalence of poor sanitation. Amebiasis thrives in such conditions, as contaminated water and food sources create an environment conducive to the spread of the Entamoeba histolytica parasite. For instance, in July 2023, the United Nations Water agency reported that in 2022, 2 billion people lacked access to basic hygiene services, while 3.5 billion did not have safely managed sanitation. This widespread issue continues to drive the demand for solutions in the amebiasis market.

Leading companies in the amebiasis market are focusing on innovative advancements such as ready-to-use oral liquid metronidazole to enhance patient compliance and treatment effectiveness. This pre-prepared liquid antibiotic formulation is designed to simplify treatment, particularly for individuals who have difficulty swallowing pills. In November 2023, Kesin Pharma Corporation, a US-based pharmaceutical company, received approval from the U.S. Food and Drug Administration for Likmez (metronidazole) oral suspension, 500 mg/5 mL. This marks the first ready-to-use oral liquid formulation of metronidazole. The oral suspension provides a pediatric-friendly alternative, making it easier for children to take the medication with accurate dosing, thereby improving adherence to treatment protocols. Additionally, the liquid formulation offers dosing flexibility, allowing healthcare providers to tailor treatment based on the severity of infections and individual patient needs.

Major players in the amebiasis market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Siemens Healthineers AG, Becton Dickinson and Company, Teva Pharmaceutical Industries Ltd., Cipla Limited, Hikma Pharmaceuticals PLC, Lupin Limited, Cepheid Inc., Mission Pharmacal Company, Profounda Inc., and Zydus Lifesciences Limited.

North America was the largest region in the amebiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in amebiasis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the amebiasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Amebiasis is an intestinal infection caused by the parasite *Entamoeba histolytica*, often resulting in symptoms such as diarrhea, abdominal pain, and, in some cases, liver abscesses. This infection is treated with medications such as metronidazole and tinidazole, which work by targeting the parasite in both the gut and tissues.

The primary drugs used to treat amebiasis include metronidazole, paromomycin, and tinidazole. Metronidazole is an antibiotic that eliminates certain bacteria and parasites by disrupting their DNA, making it an effective treatment for amebiasis. The medications can be administered through various routes, including oral and intravenous, and are commonly used in healthcare settings such as hospitals and pharmacies.

The amebiasis market research report is one of a series of new reports that provides amebiasis market statistics, including the amebiasis industry global market size, regional shares, competitors with the amebiasis market share, detailed amebiasis market segments, market trends, and opportunities, and any further data you may need to thrive in the amebiasis industry. This amebiasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The amebiasis market includes revenues earned by entities by providing services such as medical consultation and treatment management, vaccination and preventive services, pharmaceutical services, and diagnostic testing services. The market value includes the value of related goods sold by the service provider or included within the service offering. The amebiasis market also includes sales of antiprotozoal medications, diagnostic kits, vaccines, and probiotics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.